World biggest biopharmaceutical company Amgen in terms of market cap declared the establishment of a Chinese R&D center, another important step taken after forming a JV with Zhejiang Beta Pharma in May 2013.
Amgen Global Business Operation Executive Vice President Anthony C. Hooper pointed out that the company will advance in drug registration, research and development, generic drugs, production and business operation together in China in the future.
Source:
http://www.sinocast.com/readbeatarticle.do?id=99894
